Definitive N-terminal protein sequence and further characterization of the novel apolipoprotein A5 in human serum

Clinical Chemistry

Volumn 52, Issue 3, 2006, Pages 514-517

  Alborn, William E ^a   Johnson, Melvin G ^a   Prince, Melvin J ^a   Konrad, Robert J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A5; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; HUMAN; IMMUNOPRECIPITATION; PROTEIN ANALYSIS; PROTEIN PURIFICATION; SERUM; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING;

AMINO ACID SEQUENCE; APOLIPOPROTEINS; APOLIPOPROTEINS A; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; SERUM;

MUS MUSCULUS;

EID: 33644551545     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.061374     Document Type: Article

References (20)

1. Willems Van Dijk K, Rensen PC, Voshol PJ, Havekes LM. The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism. Curr Opin Lipidol 2004;15:239-46.
2. Pennacchio LA, Rubin EM. Apolipoprotein A5, a newly identified gene that affects plasma triglyceride levels in humans and mice. Arterioscler Thromb Vasc Biol 2003;23:529-34.
3. Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 2001;294:169-73.
4. van der Vliet HN, Sammels MG, Leegwater AC, Levels JH, Reitsma PH, Boers W, et al. Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration. J Biol Chem 2001;276:44512-20.
5. van der Vliet HN, Schaap FG, Levels JH, Ottenhoff R, Looije N, Wesseling JG, et al. Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. Biochem Biophys Res Commun 2001;295:1156-9.
6. O'Brien PJ, Alborn WE, Sloan JH, Ulmer M, Boodhoo A, Knierman MD, et al. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin Chem 2005;51:351-9.
7. Schultze AE, Alborn WE, Newton RK, Konrad RJ. Administration of a PPAR-α agonist increases serum apolipoprotein A5 levels and the apolipoprotein A5/apolipoprotein C3 ratio. J Lipid Res 2005;46:1591-5.
8. Prieur X, Coste H, Rodriguez JC. The human apolipoprotein AV gene is regulated by peroxisome proliferator-activated receptor-α and contains a novel farnesoid X-activated receptor response element. J Biol Chem 2003;278:25468-80.
9. Vu-Dac N, Gervois P, Jakel H, Nowak M, Bauge E, Dehondt H, et al. Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor α activators. J Biol Chem 2003;278:17982-5.
10. Pruneta-Deloche V, Ponsin G, Groisne L, Fruchart-Najib J, Lagarde M, Moulin P. Postprandial increase of plasma apoAV concentrations in type 2 diabetic patients. Atherosclerosis 2005;18:403-5.
11. Ishihara M, Kujiraoka T, Iwasaki T, Nagano M, Takano M, Ishii J, et al. A sandwich enzyme-linked immunosorbent assay for human plasma apolipoprotein A-V concentration. J Lipid Res 2005;46:2015-22.
12. Baroukh N, Bauge E, Akiyama J, Chang J, Afzal V, Fruchart JC, et al. Analysis of apolipoprotein A5, C3, and plasma triglyceride concentrations in genetically engineered mice. Arterioscler Thromb Vasc Biol 2004;24:1297-302.
13. Schaap FG, Rensen PC, Voshol PJ, Vrins C, Van Der Vliet HN, Chamuleau RA, et al. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J Biol Chem 2004;279:27941-7.
14. Fruchart-Najib J, Bauge E, Niculescu LS, Pham T, Thomas B, Rommens C, et al. Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. Biochem Biophys Res Commun 2004;319:397-404.
15. Lookene A, Beckstead JA, Nilsson S, Olivecrona G, Ryan RO. Apolipoprotein A-V-heparin interactions: implications for plasma lipoprotein metabolism. J Biol Chem 2005;280:25383-7.
16. Merkel M, Loeffler B, Kluger M, Fabig N, Geppert G, Pennacchio LA, et al. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem 2005;280:21553-60.
17. Weinberg RB, Cook VR, Beckstead JA, Martin DD, Gallagher JW, Shelness GS, et al. Structure and interfacial properties of human apolipoprotein A-V. J Biol Chem 2003;278:34438-44.
18. Klos KL, Hamon S, Clark AG, Boerwinkle E, Liu K, Sing CF. ApoA5 polymorphisms influence plasma triglycerides in young, healthy African Americans and whites of the CARDIA Study. J Lipid Res 2005;46:564-71.
19. Oliva CP, Pisciotta L, Li Volti G, Sambataro MP, Cantafora A, Bellocchio A, et al. Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia. Arterioscler Thromb Vasc Biol 2005;25:411-7.
20. Schaefer JR, Sattler AM, Hackler B, Kurt B, Hackler R, Maisch B, et al. Hyperlipidemia in patients with apolipoprotein E 2/2 phenotype: apolipoprotein A5 S19W mutation as a cofactor [Letter]. Clin Chem 2004;50:2214.